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Abstract
Background: High sensitivity C-reactive protein (hsCRP) levels are shown to be influenced by genetic variants in Europeans;
however, little is explored in Indian population.
Methods: Herein, we comprehensively evaluated association of all previously reported genetic determinants of hsCRP
levels, including 18 cis (proximal to CRP gene) and 73 trans-acting (distal to CRP gene) variants in 4,200 North Indians of
Indo-European ethnicity. First, we evaluated association of 91 variants from 12 candidate loci with hsCRP levels in 2,115
North Indians (1,042 non-diabetic subjects and 1,073 patients with type 2 diabetes). Then, cis and trans-acting variants
contributing maximally to hsCRP level variation were further replicated in an independent 2,085 North Indians (1,047
patients with type 2 diabetes and 1,038 non-diabetic subjects).
Results: We found association of 12 variants from CRP, LEPR, IL1A, IL6, and IL6R with hsCRP levels in non-diabetic subjects.
However, only rs3093059-CRP [b=0.33, P=9.6610
25] and the haplotype harboring rs3093059 risk allele [b=0.32 mg/mL,
P=1.4610
24/Pperm=9.0610
24] retained significance after correcting for multiple testing. The cis-acting variant rs3093059-
CRP had maximum contribution to the variance in hsCRP levels (1.14%). Among, trans-acting variants, rs1892534-LEPR was
observed to contribute maximally to hsCRP level variance (0.59%). Associations of rs3093059-CRP and rs1892534-LEPR were
confirmed by replication and attained higher significance after meta-analysis [bmeta=0.26/0.22; Pmeta=4.3610
27/7.4610
23
and bmeta=20.15/20.12; Pmeta=2.0610
26/1.6610
26 for rs3093059 and rs1892534, respectively in non-diabetic subjects
and all subjects taken together].
Conclusion: In conclusion, we identified rs3093059 in CRP and rs1892534 in LEPR as major cis and trans-acting contributor
respectively, to the variance in hsCRP levels in North Indian population.
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Introduction
High sensitivity C-reactive protein (hsCRP), is a key component
of non-specific host defense in humans. Elevated basal hsCRP
levels have been found in low-grade systemic inflammation and
are used as a marker of risk for various pathological conditions
including type 2 diabetes (T2D) [1,2]. These levels are genetically
determined with ,30–50% heritability [3].
Both cis- (proximal to CRP gene) and trans-acting (distal to CRP
gene) genetic variants have been identified to contribute to hsCRP
levels in different ethnic cohorts [4,5,6,7,8,9,10]. Recent genome-
wide association studies (GWAS) have confirmed the involvement
of several previously identified variants and additionally recog-
nized new variants, providing important insights into hsCRP level
regulation [11,12]. However, very little is explored in this regard in
Indian population, which is a high risk group for T2D. Elevated
levels of hsCRP were found to be associated with increased risk of
T2D in North Indian population in our previous study [13].
Moreover, our recent analysis of TNF-LTA locus identified a
variant (rs2229094) influencing hsCRP levels in this population
[14]. Thus, a more thorough examination of genetic determinants
of hsCRP levels in this population is warranted.
Herein, we comprehensively evaluated association of all
previously reported genetic determinants of hsCRP levels in
North Indians.
Materials and Methods
Ethics Statement
The study was carried out in accordance with the principles of
Helsinki Declaration and was approved by Human Ethics Commit-
tee of Institute of Genomics and Integrative Biology (CSIR) and All
India Institute of Medical Sciences Research Ethics Committee.
Informed written consent was obtained from all the participants.
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The initial investigation included 2,115 unrelated Indo-
Europeans (1,073 T2D patients and 1,042 non-diabetic subjects)
from North India residing in and around Delhi. Details of subject
recruitment have been described previously [13,14,15]. An
independent set of 2,085 samples (1,047 T2D patients and 1,038
non-diabetic subjects), recruited similar to that in the initial study,
was used for further replication. Plasma hsCRP levels were
measured using ELISA kit (Biocheck Inc., CA, USA) and Cobas
Integra 400 Plus (Roche Diagnostics, GmbH, Mannheim,
Germany).
Variant selection and genotyping
We selected all the index variants shown to be associated with
hsCRP levels till July 2009 or their proxies. Further, to capture
other variants in the selected genes, we also included additional
common variants that were prioritized based on minor allele
frequency (MAF .0.05) in at least two HapMap populations,
tagging and linkage disequilibrium (LD) pattern information, and
spacing between the variants to cover the gene. The selected
variants comprised of 18 cis variants from CRP and 73 from 11
trans-acting loci (APOE, LEPR, IL1A, IL1B, IL6, IL6R, FAM13C1,
GCKR, SLC1A3, HNF1A, and a gene-desert region of chromosome
12q23.2) (Table S1).
Genotyping of 47 variants was done using Illumina GoldenGate
assay [16]. Samples (n=90) with a poor call rate (,90%) and
variants (n=3) failing quality control were excluded from the
analysis. Average call rate for successful assays was 99.6% with
.99.9% concordance in 7.2% duplicates. The remaining 44
variants and one that failed Illumina assay were genotyped using
iPLEX (Sequenom, San Diego, USA). The average genotyping
success rate of the quality control passed variants (n=41) was
97.7%, with 99.9% consensus in 4% duplicates. Four rare variants
(MAF,0.05) and three that deviated from Hardy-Weinberg
equilibrium (P,5.9610
24; 0.05/85) were excluded, and thus 78
variants were considered for association analyses.
Further genotyping of two variants was done in an independent
sample set on iPLEX platform for replication. Average genotyping
success rate for these was 98.3% with 99.9% concordance in 5%
duplicates.
Statistical analysis
Linear-regression was performed assuming an additive model to
determine association of variants with hsCRP levels. Samples with
hsCRP level .10 mg/mL were excluded from the analysis. hsCRP
concentrations were natural logarithm transformed to ensure a
normal distribution. To assess independent contribution of each
variant, stepwise multivariate linear regression models with age,
sex, and body mass index (BMI) as covariates were constructed.
Variants with a P,0.05 were retained in the forward stepwise-
selection models. Analyses were first carried out in non-diabetic
subjects not taking lipid-lowering drugs, adjusting for age, sex,
BMI, and smoking/tobacco chewing and then in T2D patients
and all subjects, additionally adjusting for diseases status and
medication as appropriate.
Bonferroni correction was used to account for multiple testing
and a P,8.6610
24 was considered significant after correcting for
number of independent variants a=0.05/58). Pairwise linkage
disequilibrium (LD) between the SNPs for all the genes was
determined using Haploview 4.0 (Figure S1). Association of
haplotypes with frequency .0.1 was examined through sliding
window approach using PLINK by adjusting for age, sex, BMI,
smoking/tobacco chewing, diseases status, and medication, as
appropriate, based on 10,000 permutations. Fixed and random
effect meta-analysis was performed for the two replicated variants,
in non-diabetic subjects, T2D patients and all subjects.
Statistical power of the study was evaluated using QUANTO
version 1.2 [17]. Our study had 78% and 92% power to detect
association for a variant with MAF=0.2 and effect size of 0.3 mg/
mL for additive model for non-diabetic subjects and for all subjects
analyzed together respectively. Statistical analyses were performed
using SPSS version 17.0 (SPSS, Chicago, IL) and PLINK [18].
Results
A brief description of study populations is presented in Table
S2.
Cis-acting effects
CRP variants rs3093059 and rs3093077, that were in strong LD
(r
2=0.89), showed strongest associations with hsCRP in non-
diabetic subjects [b=0.32 mg/mL, P=1.6610
24 and b=0.26,
P=1.3610
23 respectively; Table 1]. Nominal associations were
observed for variants rs3116654, rs4131568, and rs1205. A total of
2.42% of the residual variation in hsCRP could be explained by
variants rs3093059, rs3116654, and rs4131568. Variant rs3093059
contributed maximally (1.14%) to hsCRP level variance and also
retained significant association with hsCRP levels after accounting
for multiple testing. The haplotype GATCTTCG encompassing
rs3093059 risk allele also showed association with hsCRP levels
[b=0.32, P=1.4610
24/Pperm=9.0610
24; Table S3]. We ob-
served similar results when separate analyses for T2D patients and
all the subjects were performed (Table 1). Further, we tested
association of haplotypes of different lengths to detect a signal that
could not be observed by single marker analysis. The b and P values
for haplotype associations were found to be similar as the individual
associated SNPs (Figure S2). We did not find any haplotype that
could detect region or signal in addition to single marker analysis.
Trans-acting effects
Three LEPR, two IL6R, one IL6, and one IL1A variants showed
association with hsCRP levels (P,0.05; Table 1). All three LEPR
and two IL6R variants (rs4129267, and rs4845622) were in strong
LD (r
2=0.91–0.96 and 0.96 respectively). The most significant
association was detected for LEPR-rs1892534 [b=20.16,
P=5.5610
23], however, none of the associations retained
significance after accounting for multiple testing. These loci
accounted for a total of 1.63% hsCRP level variance, with 0.59%,
0.56%, and 0.48% variance attributed to rs1892534-LEPR,
rs1800796-IL6, and rs4129267-IL6R respectively. LEPR, IL6 and
IL6R also showed association with hsCRP levels when all subjects
were analyzed together. The most significant association was
observed for rs769449-APOE [b=20.27, P=1.2610
23]. Howev-
er, none of these retained significance after correcting for multiple
testing. Similar results were obtained when analyses were
performed separately in T2D patients (Table 1). The haplotype
GGGCCA-IL6 was associated with hsCRP levels when all the
subjects were analyzed together [b=20.16, P=3.9610
24/
Pperm=1.2610
23]. We did not find any haplotype that could
detect region or signal in addition to single marker analysis (Figure
S2).
Follow up and Meta-analysis
The rs3093059-CRP and rs1892534-LEPR, strongest associated
cis and trans-acting variants respectively, were successfully
replicated in an independent sample of North Indians (Table 2).
Meta-analysis further strengthened the associations in non-diabetic
subjects [bmeta=0.26, Pmeta=4.3610
27 and bmeta=20.15,
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26 for rs3093059 and rs1892534, respectively, for
random effect]. No heterogeneity was detected between two study
populations (I
2=0). Similarly, significant associations were
observed when all subjects were analyzed together, however only
nominal association of rs1892534-LEPR was observed when
analysis was performed separately in T2D patients (Table 2).
Discussion
Recent GWAS and other previous candidate gene based
investigations have demonstrated role of cis-acting variants of
CRP and trans-actingvariants from genes includingLEPR, IL6R, IL6
etc in regulation of hsCRP levels. Our study demonstrated strong
association of a cis-acting variant rs3093059-CRP and a trans-acting
variant rs1892534-LEPRwith hsCRPlevelsinNorthIndians.These
two variants contributed maximally to the variance in hsCRP levels.
Several studies have shown strong association of variants at CRP
locus with plasma levels of hsCRP [7,19–22]. Our study also
demonstrates cis acting variants to greatly influence plasma hsCRP
levels. Among them, rs3093059 showed strongest association with
hsCRP levels that was confirmed in an independent study
population. The results in the combined analysis of T2D patients
and non-diabetic subjects were comparable to that seen in non-
diabetic subjects alone. Our observations are consistent with
previous reports demonstrating that both CRP variants and
haplotypes are associated with hsCRP levels [7,19].
Among the trans acting variants, strongest association was
observed at rs1892534 of LEPR. Leptin receptor signaling has
been linked to appetite control, weight regulation, glucose
homeostasis, vascular risk, and hsCRP levels [8,11]. Previous
reports provided evidence for the association of rs1892534 with
hsCRP levels in European populations [8,11]. Thus, our results
Table 1. Variants associated with hsCRP levels.
Gene Polymorphism MAF*
Median
hsCRP level
(mg/mL)*
Non-
diabetic
subjects
(n=910)
T2D
subjects
(n=790)
All subjects
(n=1,700)
11 12 22 b
{ P value
{ b
I P value
I b
1 P value
1
CRP rs2592887 0.34 1.12 1.27 0.96 20.05 0.37 20.24 4.9610
24 20.13 4.3610
23
rs2794520 0.29 1.17 1.18 0.96 20.11 0.06 20.20 4.2610
23 20.15 1.1610
23
rs3093077 0.13 1.09 1.53 1.43 0.26 1.3610
23 0.26 0.01 0.26 3.8610
25
rs1205 0.29 1.17 1.19 0.97 20.12 0.05 20.21 1.9610
23 20.16 5.3610
24
rs3091244 { 0.34 1.10 1.16 1.41 0.08 0.14 0.13 0.06 0.10 0.03
rs3093059 0.12 1.09 1.61 1.32 0.32 1.6610
24 0.29 7.1610
23 0.31 2.8610
26
rs3116654 0.10 1.17 1.19 0.30 20.23 0.02 20.07 0.59 20.18 0.02
rs4131568 0.27 1.25 1.15 1.11 20.13 0.03 20.06 0.40 20.11 0.02
LEPR rs1805096 0.48 1.35 1.17 1.13 20.13 0.02 20.11 0.06 20.12 3.2610
23
rs1892534 0.48 1.36 1.15 1.13 20.16 5.5610
23 20.12 0.07 20.14 1.3610
23
rs12753193 0.48 1.42 1.14 1.13 20.15 8.3610
23 20.10 0.12 20.13 3.1610
23
IL6R rs4845371 0.50 1.20 1.26 1.10 20.11 0.06 20.09 0.16 20.10 0.02
rs6667434 0.50 1.20 1.26 1.10 20.11 0.06 20.09 0.16 20.10 0.02
rs7529229 0.31 1.26 1.17 1.08 20.14 0.02 20.03 0.69 20.10 0.04
rs4129267 0.29 1.25 1.12 1.10 20.13 0.04 20.02 0.79 20.09 0.08
rs4845622 0.32 1.24 1.13 1.08 20.12 0.04 20.03 0.75 20.08 0.07
IL1A rs1800587 0.33 1.20 1.11 1.45 0.12 0.04 20.04 0.57 0.06 0.20
IL6 rs1800797 0.17 1.15 1.21 1.53 0.06 0.43 0.25 3.8610
23 0.14 0.01
rs2069827 0.05 1.17 1.41 1.36 0.02 0.83 0.31 0.03 0.13 0.14
rs2069845 0.24 1.18 1.11 1.43 20.005 0.94 0.15 0.05 0.06 0.24
rs1800796 0.28 1.32 1.08 1.23 20.14 0.02 20.15 0.02 20.14 1.5610
23
APOE rs157580 0.46 1.08 1.15 1.44 0.08 0.12 0.18 5.1610
23 0.12 3.7610
23
rs2075650 0.11 1.17 1.10 1.62 20.11 0.20 20.24 9.8610
23 20.17 7.8610
23
rs769449 0.07 1.18 1.03 1.33 20.19 0.09 20.39 1.7610
23 20.27 1.2610
23
GCKR rs13013484 0.33 1.23 1.10 1.26 20.007 0.91 20.19 5.7610
23 20.07 0.09
IL1B rs1143642 0.11 1.16 1.15 1.49 0.01 0.87 0.24 0.02 0.11 0.10
MAF: Minor allele frequency; 11: Homozygous major; 12: Heterozygous; 22: Homozygous minor; b: Beta.
*Analyzed in only non-diabetic subjects.
{Tri-allelic variant. The two less-common alleles (T and A) were pooled.
{P value and b calculated after adjusting for age, sex, BMI, and smoking/tobacco chewing.
IP value and b calculated after adjusting for age, sex, BMI, smoking/tobacco chewing, and medication
1 P value and b calculated after adjusting for age, sex, BMI,
smoking/tobacco chewing, medication, and diseases status.
P values retaining significance after correcting for multiple testing are given in bold.
doi:10.1371/journal.pone.0024645.t001
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traits through genetic modulation of hsCRP levels.
We found nominal association of other trans-acting loci namely
IL1A, IL6, IL6R, and APOE with hsCRP levels in non-diabetic
North Indians. All these variants contributed to ,2% of hsCRP
level variance. The analysis of all subjects taken together
essentially substantiated the results seen in non-diabetic subjects.
IL6R and APOE variants were shown to be associated with hsCRP
levels in apparently healthy Caucasian women in an agnostic
approach [11]. This is perhaps the first study to replicate the
association of rs1800587-IL1A variant [5], though it could not
attain the statistical significance after multiple testing corrections.
The effects of all associations were directionally consistent and the
effect sizes were almost comparable to earlier studies [5,8,11].
Hence, our study validates the observations in European popu-
lations, suggesting involvement of overlapping genetic mechanisms
in regulating hsCRP levels in Europeans and North Indians.
Though we replicated the association of CRP, LEPR, IL1A, IL6,
IL6R, and APOE, we could not detect association of the most
widely implicated tri-allelic CRP variant rs3091244. The tri-allelic
variant rs3091244 has been repeatedly shown to be associated
with plasma hsCRP levels and an in vitro study suggested its
functional role in transcription factor binding [20]. There was no
difference in allele frequencies between Caucasians and North
Indians at this locus but we observed differences in LD pattern
around this variant in the CRP gene between the two populations
(Figure S1). A recent GWAS study for hsCRP plasma levels also
indicated the differences in genetic background in CRP between
different ethnic groups [21]. Thus the ethnic differences in genetic
architecture at this locus could be the reason for difference in
association results.
Moreover recent studies have discovered GCKR as a novel
hsCRP modulating candidate gene and have provided confir-
matory evidence for the association of HNF1A [9,11]. However,
variants from both these loci were not associated in our study.
Allele frequencies at these loci differed significantly between the
Caucasians and North Indians and could have potentially limited
the power to detect association, if any. Differences in LD
patterns between the populations could potentially lead to
differences in results but the comparison of LD around these
genes showed similar patterns in Indians and Europeans (Figure
S1) and thus do not account for the observed differences in
association results.
Limited statistical power and population stratification might
also lead to the disparity in the association results. There is a
likelihood of false negative observations for variants with small
effect sizes, as our study is sufficiently powered to capture only
large effects (.0.25 mg/mL) of the common variants with
frequencies more than 0.20. Our study is, however, unlikely to
be influenced by population stratification, because the study
population is highly homogeneous, as previously demonstrated
[15,23]. We have included only North Indian subjects belonging
to Indo-European ethnicity from Delhi and surrounding regions
that form a homogenous cluster as reported by the Indian
Genome Variation Consortium [23].
Further, we would like to mention that although we attempted
to cover entire gene and investigate all the reported associated
variants, we could not type few of them due to assay failures.
Moreover, the ascertainment procedure of the subjects that
recruited subjects based on the presence or absence of T2D could
potentially affect the estimation of effect sizes. We could not
determine the population level effect sizes that could have
provided added information from the study. However, with the
major focus of the study to determine the genetic variants
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essentially a limitation of the study.
Epidemiological studies have consistently demonstrated that the
risk of T2D and cardio-vascular disease (CVD) increase with
higher hsCRP levels. In a study conducted on samples inclusive of
those studied here, we earlier demonstrated that hsCRP levels
were associated with T2D in a BMI independent manner [13]. In
the light of hsCRP being a potential biomarker for CVD and
T2D, the search for genetic variants influencing its expression is of
great importance. With the realization that variant frequencies
and haplotype structures vary considerably between ethnic groups,
the present study provides a clear picture of genetic factors
associated with plasma hsCRP levels in Indian population.
Identification of genetic regulators of hsCRP levels might help in
the development of prognostic markers for detecting individuals at
risk for CVD and T2D.
In conclusion, we identified rs3093059 in CRP and rs1892534 in
LEPR as the major cis and trans-acting contributor respectively, to
the variance in hsCRP levels in North Indian population. Still
further studies investigating variants from CRP and its regulatory
genes are warranted to explain the total genetic control of
circulating hsCRP levels.
Supporting Information
Figure S1 Pairwise linkage disequilibrium (LD) between the
selected SNPs in the genes investigated in the study. Left panel
shows the plots with D’ values and right panel shows plot with
r
2values. LD plots for North Indians were drawn using the
genotype data from the present study whereas LD plots for
Europeans were made from genotype data from HapMap.
(DOC)
Figure S2 Association of individual associated SNPs and their
haplotypes with hsCRP levels. A: CRP and B: IL6. The 2log10 P
values are plotted against the respective SNPs and haplotype
combinations formed by that SNP and all the SNPs before. The
trend lines of 2log10 P values for individual SNPs and highest
2log10 P values for haplotypes are drawn for the comparison of
association of SNPs and haplotypes.
(DOC)
Table S1 Details of the polymorphisms selected for this study.
MAF: Minor Allele Frequency; HWE: Hardy-Weinberg equilib-
rium. * MAF, Genotype distribution and HWE estimations have
been done in non-diabetic subjects alone.
{ Tri-allelic variant. The
two less-common alleles (T and A) were pooled.
{ MAF,0.05.
1Assay failure.
I Significant deviation from HWE. Chromosome
positions are relative to NCBI Build 36.3 assembly, dbSNP b126.
(DOC)
Table S2 Descriptive characteristics of the study populations.
Data are presented as median values (inter-quartile ranges). N:
Number of subjects; TC: total cholesterol; LDL-C: low-density
lipoprotein cholesterol; HDL-C: high-density lipoprotein choles-
terol; TG: triglyceride; hsCRP: high sensitivity C-reactive protein.
(DOC)
Table S3 Haplotype association with hsCRP levels. b: Beta. b
and P values presented were adjusted for age, sex, BMI, and
smoking/tobacco chewing for analysis done in non-diabetic
subjects; age, sex, BMI, smoking/tobacco chewing, and medica-
tion for diabetic subjects; and age, sex, BMI, smoking/tobacco
chewing, disease status, and medication for all subjects taken
together. Pperm: P value obtained after 10,000 permutations.
(DOC)
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